Please login to the form below

Not currently logged in

AbbVie begins 'first-of-its-kind' hep C charity pilot

Will work with Addaction Cornwall and The Hepatitis C Trust

Hepatits C AbbVie NHS partnership
Addaction's David Baldock (left) and Len Gooblar, head of strategic health initiatives at AbbVie

AbbVie is piloting a new UK programme to validate different approaches to improving hepatitis C testing and treatment in those with a history of injection drug use.

The pharma company will partner with two charities on the programme, which it described as 'a first-in-class pilot' that will use an evidence-based approach encompassing workforce training, peer-to-peer education and buddying (one-on-one support that helps people through their hospital and treatment journey).

Drug users are a typically hard to reach population who find it difficult to access traditional models of care.

AbbVie, Addaction Cornwall - the local branch of the national drug and alcohol charity, and The Hepatitis C Trust are hoping that the successful completion of their pilot programme will be followed by a national roll-out in 2015.

It is estimated that in England there are 160,000 people living with chronic hepatitis C infection, 19,705 of them in the South West, and 1,398 in Cornwall.
Sue Clark, operations director, Addaction Cornwall, said: “We are proud to be leading the way in piloting a ground-breaking partnership programme to improve the health of our communities, while contributing toward a longer-term vision of eliminating the hepatitis C virus (HCV) in the South West.”
Beyond testing and treating people with a history of injection drug use, the new programme hopes to free up NHS resources and reduce community-acquired transmission of hepatitis C.

Article by
Tara Craig

7th August 2014

From: Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...